{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:24:55Z","timestamp":1784309095790,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jacl.2021.12.004","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T12:19:40Z","timestamp":1641298780000},"page":"173-183","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins"],"prefix":"10.1016","volume":"16","author":[{"given":"Samar M","family":"Hammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly J","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel L","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5572-1700","authenticated-orcid":false,"given":"Maria F","family":"Lopes-Virella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2021.12.004_bib0001","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/978-1-4419-6741-1_14","article-title":"Therapeutic strategies for diabetes and complications: a role for sphingolipids?","volume":"688","author":"Fox","year":"2010","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1016\/j.jacl.2021.12.004_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107734","article-title":"Role of ceramides in the pathogenesis of diabetes mellitus and its complications","volume":"35","author":"Mandal","year":"2021","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jacl.2021.12.004_bib0003","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.metabol.2014.07.001","article-title":"Decreased plasma levels of select very long chain ceramides species are associated with the development of nephropathy in type 1 diabetes","volume":"63","author":"Klein","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2021.12.004_bib0004","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.jacl.2019.03.005","article-title":"Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes","volume":"13","author":"Lopes-Virella","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2021.12.004_bib0005","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.tem.2017.03.005","article-title":"Hussain MM. Sphingolipids and Lipoproteins in Health and Metabolic Disorders","volume":"28","author":"Iqbal","year":"2017","journal-title":"Trends Endocrinol Metab"},{"issue":"216","key":"10.1016\/j.jacl.2021.12.004_bib0006","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/978-3-7091-1511-4_19","article-title":"Sphingolipids in obesity, type 2 diabetes, and metabolic disease","author":"Russo","year":"2013","journal-title":"Handb Exp Pharmacol"},{"issue":"13","key":"10.1016\/j.jacl.2021.12.004_bib0007","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/BF01469685","article-title":"Plasma glycosphingolipids in diabetics and normals","volume":"53","author":"Kremer","year":"1975","journal-title":"Klin Wochenschr"},{"issue":"2","key":"10.1016\/j.jacl.2021.12.004_bib0008","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2337\/db08-1228","article-title":"Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance","volume":"58","author":"Haus","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.jacl.2021.12.004_bib0009","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/978-3-030-21162-2_7","article-title":"Sphingolipids as Biomarkers of Disease","volume":"1159","author":"Matanes","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jacl.2021.12.004_bib0010","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1194\/jlr.D008532","article-title":"Blood sphingolipidomics in healthy humans: impact of sample collection and methodology","volume":"51","author":"Hammad","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2021.12.004_bib0011","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.chemphyslip.2008.06.003","article-title":"Reconsideration of hydrophobic lipid distributions in lipoprotein particles","volume":"155","author":"Kumpula","year":"2008","journal-title":"Chem. Phys. Lipids."},{"key":"10.1016\/j.jacl.2021.12.004_bib0012","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1042\/bj3520809","article-title":"Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions","volume":"352","author":"Murata","year":"2000","journal-title":"Biochem J"},{"key":"10.1016\/j.jacl.2021.12.004_bib0013","doi-asserted-by":"crossref","first-page":"25863","DOI":"10.1074\/jbc.M115.659110","article-title":"Microsomal triglyceride transfer protein transfers and determines plasma concentrations of ceramide and sphingomyelin but Not glycosylceramide","volume":"290","author":"Iqbal","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2021.12.004_bib0014","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1194\/jlr.M087502","article-title":"ATP binding cassette family A protein 1 determines hexosylceramide and sphingomyelin levels in human and mouse plasma","volume":"59","author":"Iqbal","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2021.12.004_bib0015","series-title":"2014 USRDS annual data report: epidemiology of kidney disease in the United States","year":"2014"},{"issue":"3","key":"10.1016\/j.jacl.2021.12.004_bib0016","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1021\/pr201036j","article-title":"Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study)","volume":"11","author":"M\u00e4kinen","year":"2012","journal-title":"J Proteome Res"},{"key":"10.1016\/j.jacl.2021.12.004_bib0017","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11306-011-0343-y","article-title":"Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study)","volume":"8","author":"M\u00e4kinen","year":"2012","journal-title":"Metabolomics"},{"issue":"9","key":"10.1016\/j.jacl.2021.12.004_bib0018","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00125-020-05201-9","article-title":"Groop PH; FinnDiane Study Group. Sphingomyelin and progression of renal and coronary heart disease in individuals with type 1 diabetes","volume":"63","author":"Pongrac Barlovic","year":"2020","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.jacl.2021.12.004_bib0019","doi-asserted-by":"crossref","first-page":"16398","DOI":"10.1038\/s41598-019-52916-w","article-title":"Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes","volume":"9","author":"Tofte","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jacl.2021.12.004_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.aca.2011.01.034","article-title":"Plasma esterified and non-esterified fatty acids metabolic profiling using gas chromatography-mass spectrometry and its application in the study of diabetic mellitus and diabetic nephropathy","volume":"689","author":"Han","year":"2011","journal-title":"Anal Chim Acta"},{"issue":"4","key":"10.1016\/j.jacl.2021.12.004_bib0021","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.talanta.2011.05.036","article-title":"Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy","volume":"85","author":"Zhu","year":"2011","journal-title":"Talanta"},{"issue":"3","key":"10.1016\/j.jacl.2021.12.004_bib0022","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.ekir.2016.12.003","article-title":"Profiling of plasma metabolites suggests altered mitochondrial fuel usage and remodeling of sphingolipid metabolism in individuals with type 2 diabetes and kidney disease","volume":"2","author":"Liu","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"21","key":"10.1016\/j.jacl.2021.12.004_bib0023","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130317","article-title":"Increased lipogenesis and impaired beta-oxidation predict type 2 diabetic kidney disease progression in American Indians","volume":"4","author":"Afshinnia","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jacl.2021.12.004_bib0024","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1194\/jlr.M003988","article-title":"HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphingosine-1-phosphate","volume":"51","author":"Lee","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2021.12.004_bib0025","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2337\/diab.32.1.20","article-title":"Effect of Metabolic Control on lipid, lipoprotein, and apolipoprotein levesl in 55 insulin-dependent diabetic patients. A longitudinal study","volume":"32","author":"Lopes-VIrella","year":"1983","journal-title":"Diabetes"},{"key":"10.1016\/j.jacl.2021.12.004_bib0026","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/180705","article-title":"Sphingosine 1-phosphate distribution in plasma: associations with atypical lipoprotein profiles","author":"Hammad","year":"2012","journal-title":"J Lipids"},{"key":"10.1016\/j.jacl.2021.12.004_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224496","article-title":"Race disparity in blood sphingolipidomics associated with lupus cardiovascular comorbidity","volume":"14","author":"Hammad","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2021.12.004_bib0028","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jacl.2019.02.004","volume":"13","author":"Zakiev","year":"2019","journal-title":".Journal of Clinical Lipidology"},{"key":"10.1016\/j.jacl.2021.12.004_bib0029","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1194\/jlr.P119000543","article-title":"LDL subclass lipidomics in atherogenic dyslipidemia:effect of statin therapy on bioactive lipids and dense LDL","volume":"61","author":"Chapman","year":"2020","journal-title":"J. Lipid Res"},{"issue":"2","key":"10.1016\/j.jacl.2021.12.004_bib0030","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1681\/ASN.V72171","article-title":"Sphingolipids: their role in intracellular signaling and renal growth","volume":"7","author":"Shayman","year":"1996","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.jacl.2021.12.004_bib0031","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1038\/sj.ki.5001834","article-title":"Lipotoxicity","volume":"70","author":"Weinberg","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacl.2021.12.004_bib0032","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-physiol-031620-093815","article-title":"Ceramides in metabolism: key lipotoxic players","volume":"83","author":"Chaurasia","year":"2021","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.jacl.2021.12.004_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.622692","article-title":"Rotten to the cortex: ceramide-mediated lipotoxicity in diabetic kidney disease","volume":"11","author":"Nicholson","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"10.1016\/j.jacl.2021.12.004_bib0034","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00395-008-0769-1","article-title":"The S1P(2) receptor expressed in human platelets is linked to the RhoA-Rho kinase pathway and is down regulated in type 2 diabetes","volume":"104","author":"Randriamboavonjy","year":"2009","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jacl.2021.12.004_bib0035","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1475-2840-12-27","article-title":"High-density lipoprotein of patients with type 2 diabetes mellitus upregulates cyclooxgenase-2 expression and prostacyclin I-2 release in endothelial cells: relationship with HDL-associated sphingosine-1-phosphate","volume":"12","author":"Tong","year":"2013","journal-title":"Cardiovasc Diabetol"},{"issue":"5","key":"10.1016\/j.jacl.2021.12.004_bib0036","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/ATVBAHA.115.307049","article-title":"Diabetes mellitus is associated with reduced high-density lipoprotein sphingosine-1-phosphate content and impaired high-density lipoprotein cardiac cell protection","volume":"36","author":"Brinck","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"10.1016\/j.jacl.2021.12.004_bib0037","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0192616","article-title":"Type 2 diabetes is associated with loss of HDL endothelium protective functions","volume":"13","author":"Vaisar","year":"2018","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jacl.2021.12.004_bib0038","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.atherosclerosis.2015.06.040","article-title":"Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration","volume":"241","author":"Denimal","year":"2015","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.jacl.2021.12.004_bib0039","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/genes11020178","article-title":"Transcriptomics reveal altered metabolic and signaling pathways in podocytes exposed to C16 ceramide-enriched lipoproteins","volume":"11","author":"Hammad","year":"2020","journal-title":"Genes (Basel)"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287421003512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287421003512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:36:26Z","timestamp":1761831386000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287421003512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1933287421003512"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2021.12.004","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetes and kidney dysfunction markedly alter the content of sphingolipids carried by circulating lipoproteins","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2021.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}